Introduction
The term acute myeloid leukemia (AML) encompasses a range of clonal hematopoietic disorders with aberrant proliferation and differentiation. The malignant clone outgrows the normal hematopoietic cells resulting in an accumulation of immature cells in the hematopoietic tissues. Over the past decade progress in both therapy and diagnosis have improved the outlook for certain AML patients. However, despite these improvements the overall survival rate is still only 40 percent in patients with an age of less than 65 years whilst for patients with an age of 65 years and beyond this survival is below 10%. 1 A number of clinical, hematological and (cyto)genetical features reflecting the heterogeneity of the disease are used to predict the outcome of therapy. Adverse prognostic factors include (1) an age over 60 years, (2) AML resulting from a prior hematological disorder such as MDS and (3) a high white blood cell count. 2 Adverse cytogenetics, eg deletions of chro- The fms-like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 (STK1) or fetal liver tyrosine kinase-2 (FLK-2), [3] [4] [5] [6] belongs to the group of class III receptor tyrosine kinases (RTKs) which also include the receptors c-kit and cfms. Signals generated by ligand-induced dimerisation of these receptors involve tyrosine phosphorylation of certain regions of the receptor and activation of cellular tyrosine kinases. While a large proportion of AML cases has been found to express class III RTKs, [7] [8] [9] [10] their potential role in leukemia development is still unclear. Recently it has been reported that internal tandem duplications in the Flt3 gene (Flt3/ITDs) occur in 17-20% of AML patients and are significantly associated with a poor patient prognosis. [11] [12] [13] Except in AML, these duplications have also been found in patients with leukemic transformation of myelodysplasia, 14 but not in patients suffering from acute lymphoid leukemia, chronic myeloid leukemia (CML), blast crisis CML, or in normal individuals. We have shown that AML cells with Flt3/ITDs have a reduced proliferative ability in both long-term stroma-supported cultures 15 and short-term stroma-free cultures. 11 The apparent contrast between this reduced proliferative ability in vitro and the poor prognosis of AML patients with Flt3/ITDs led us to investigate whether exclusion of Flt3/ITD samples would lead to a better correlation between either autonomous or cytokine-induced proliferation, and patient prognosis. Specifically, we have examined the possibility of further distinguishing the prognosis of patients that are currently assigned to the 'intermediate risk' group on the basis of cytogenetics. For this purpose we have correlated the in vitro autonomous proliferation in combination with the proliferative response to a panel of 10 cytokines to (1) response to remission induction treatment, (2) relapse probability, (3) overall survival (OS) and (4) failurefree survival (FFS) of 103 patients with de novo AML.
Materials and methods

Patient samples
Diagnosis bone marrow samples of patients with AML were obtained after informed consent. Cases were classified according to the French-American-British (FAB) committee recommendations. 16 Mononuclear cells were isolated by Ficoll separation followed by T cell depletion, typically resulting in a population containing over 95% blasts. After isolation cells were subjected to controlled freezing and stored in liquid nitrogen. Before use cells were thawed by stepwise dilution in Iscove's modified Dulbecco's medium (IMDM; Gibco, Breda, The Netherlands) containing 1% BSA. Post-thawing viability varied between 70 and 90% as assessed by dye exclusion.
After diagnosis patients were treated according to studies of the adult Dutch-Belgian Haemato-Oncology Group HOVON, ie the HOVON-29 (less then 60 years of age, 45 patients), 17 HOVON-4 (less then 60 years, 44 patients), 18 HOVON-31 (60 years+, 11 patients) and the AML-11 (60 years+, three patients) 19 protocols. In these protocols induction therapy included an anthracycline and cytarabine, while in patients less then 60 years allogeneic and autologous stem cell transplantation or intensive chemotherapy for consolidation were applied as post-remission therapy. In the HOVON-29 study induction therapy consisted of Ara-C (200 mg/m 2 ) for 7 days combined with idarubicin (12 mg/m 2 ) for the last 3 days (cycle I) followed by a second cycle consisting of Ara-C (6 days, 1000 mg/m 2 ) combined with amsacrine ( 
Stratification according to karyotype risk groups
As cytogenetic aberrations are thought to be important prognostic factors for AML 20, 21 patients were stratified in three groups, ie a good risk group consisting of patients defined by a karyotype of t(8;21), t(15;17) or inv(16) and a poor risk group defined by del(5), del(7), or deletions of the q arms of these chromosomes, t (6, 9) , alterations in the 11q23 region or the presence of multiple aberrations (more than three) in the karyotype. All other karyotypic aberrations and a normal karyotype were included in an intermediate risk group.
Determination of Flt3 mutants
All AML samples were analyzed for mutations in exons 11 and 12 of the Flt3 gene by using a modified PCR procedure as described elsewhere. 22 The use of exon 11 and 12 specific primers allowed us to cover the whole JM and the first part of the TK-1 domain where most of the reported ITDs are located.
Genomic DNA was prepared using a standard procedure. 23 Briefly, DNA from about 10 4 cells was amplified in a total of 50 l reaction mixture, containing single strength PCR buffer, 10 pmol of each primer, 10 mM dNTPs and 0.5 U Taq polymerase (Supertaq, SpheroQ, Leiden, The Netherlands). Preheating of the samples at 95°C was followed by amplification for 35 cycles consisting of 1 min at 43°C, 1 min at 72°C and 1 min at 95°C. Following these cycles a final extension at 72°C was performed for 10 min. PCR products were stained with SYBR green I (Molecular Probes, Leiden, The Netherlands) and resolved on 3% agarose gel. As a confirmation samples positive for a Flt3 mutation were re-analyzed in a second PCR using the primers 11F and 12R. Cytogenetic stratification was performed according to the criteria described in the Materials and methods section.
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Short-term proliferative response to single cytokine stimulation
To determine the proliferative response of AML bone marrow samples to single cytokine stimulation we used a thymidine incorporation assay. As monocytes are known to produce many cytokines and thus potentially may perturb the results, we removed these cells prior to their use in culture by adhesion to plastic (1 h incubation at 37°C in alpha-MEM (Gibco) + 1% BSA (Sigma, St Louis, MO, USA)). FAB M5 samples were excluded from this treatment as the leukemic cells from this monocytic leukemia also adhere to the plastic. The non-adherent cells were plated in 96-well plates at a density of 2 × 10 4 cells/well in serum-free medium 24 and cultured for 6 days. The cytokines used were either hIL-1␣ (100 U/ml), hIl-7 (100 U/ml), hGM-CSF (10 ng/ml) all a generous gift from Immunex (Seattle, WA, USA); hIl-11 (10 ng/ml), hM-CSF (100 U/ml), hIL-3 (25 ng/ml) all a gift from Genetics Institute, Cambridge, MA, USA; TNF␣ (1000 U/ml, Boehringer, Ingelheim, Germany), hEPO (1 U/ml, Janssen Cilag, Berchem, Belgium), hG-CSF (100 ng/ml) or hSCF (100 ng/ml) both a gift from Amgen (Thousand Oaks, CA, USA). After 6 days the cells were incubated overnight with 0.1 Ci tritiated-thymidine (Amersham, Buckinghamshire, UK) per well and harvested on to nitrocellulose filters. Thymidine incorporation was determined using a liquid scintillation counter (Pharmacia-LKB, Bromma, Sweden) as counts per minute (c.p.m.). All cultures were done in triplicate.
Statistical analysis
Statistical analysis of the data was performed using the SPSS software package (SPSS, Chicago, IL, USA). The usual 2 test For this analysis the rank number of the growth factor response was used as input variable for the regression analysis. a Values considered to be statistically significant.
was used to evaluate complete remission (CR) and relapse rates. For the survival analysis the Kaplan-Meier method of the same software package was used. The logrank test was used to check for equality of the survival distributions. Overall survival was calculated from the date of diagnosis to the date of (leukemia-related) death. The failure-free survival (FFS) was calculated from the date of diagnosis to the date of relapse.
Patients not achieving CR were scored as having an FFS of 0.01. Patients dying from non-leukemia-related causes during first CR were included until date of death. Patients not showing any event were considered 'censored' observations at the date of last follow up.
Initial screening of the correlations between growth factor responses and prognosis was performed by multivariate Cox regression analysis using the rank numbers of the growth factor responses as a variable to test for trend. Growth factors which showed a significant correlation in this initial screening were studied in further detail by stratification of the patients in high and low responders based on the optimal cut-point for the cytokine response. In this analysis the optimal cut-point is defined as the amount of thymidine incorporation, measured as c.p.m., at which the difference in patient prognosis between low and high responders is largest. Patients with a growth factor response up to and including the cut-point were considered to be low responders whilst all others were considered to be high responders.
Multivariate Cox regression analysis was also used to identify other predictor variables present in the total study population and for the calculation of the relative hazards of these variables. In all evaluations values were considered significant if P values were below 0.05.
Results
Characterization of patients
Bone marrow samples from 103 patients with primary AML were screened for the presence of an Flt3/ITD. Of the 103 samples, 25 patients (25%) were found to have such a mutation. All Flt3/ITDs were in the exon 11 region of the gene, none in exon 12. As previously shown 15,25 the mutation was randomly distributed over the FAB classes and there was no apparent correlation with any known cytogenetic aberration. In most of the Flt3/ITD-positive patients the mutation was present as a heterozygous mutation but in five cases the ITD appeared as a single aberrant band on gel, indicating the presence of either a homozygous mutation or, more likely, a hemizygous deletion of the wild-type gene.
The characteristics of these 25 AML patients with an Flt3/ITD and the 78 AML patients without such a mutation included in this study are shown in Table 1 .
Short-term proliferative response of primary AML
We have recently shown 11 that the presence of Flt3/ITDs in AML correlates with a reduced proliferative ability of AML in short-term cultures (7 days) without stromal support. We have now extended the analysis to 10 cytokines (Table 2 ). In almost all cases the Flt3/ITD-positive samples showed a tendency for a decreased response to cytokines as compared to those from non-mutant cases. However, impaired cytokine responsive- ness of Flt3/ITD AML-blasts was only significant for G-CSF and GM-CSF (respective P values 0.02 and 0.05). Within the Flt3-wildtype population, the strongest responses were observed for Il-3, GM-CSF or G-CSF and the lowest median responses were seen when AML cells were stimulated with Il-7, Il-11 or TNF␣ all of them even showed a median Ͻ0, indicating inhibition). None of the cytokine responses revealed a correlation with age, white blood cell counts at diagnosis or cytogenetics (data not shown). Correlations could not be detected between proliferative ability and FAB classification except for an increased autonomous proliferation in the FAB M5 samples. This observation can be explained by the fact that in the preparation of the FAB M5 samples the plastic adhesion step was omitted, as explained in the Materials and methods section, thus allowing for the presence of cytokine-producing monocytes.
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Figure 2
Cumulative failure-free survival of primary AML patients with or without internal tandem duplications. Solid lines, Flt3 wildtype population. Dotted lines, population with Flt3/ITD. In the insert values under 'N' depict the total number of samples in each population whilst the values under 'O' depict the numbers of observed events in each population.
Clinical response and prognosis of AML patients
Within our total study population, multivariate analysis with the rank number of the cytokine responses as variables, only showed the autonomous proliferation to be a significant predictor for prognosis (Table 3) . None of the panel of 10 cytokines tested proved to be a significant predictor. For further survival analysis patients were classified into low and high autonomous proliferation groups according to the criteria described in the Materials and methods section (optimal cutpoint 3000 c.p.m.). The latter analysis showed an even better distinction in both failure-free and overall survival between low and high autonomous responders (Figure 1) .
To be able to more accurately define the intermediate risk group within our study population we performed a multivariate analysis with age, FAB classification, gender, the presence of Flt3/ITD and conventional cytogenetics as variables in the regression analysis. Of these variables poor risk cytogenetics, an age over 60 years and the presence of Flt3/ITDs (Figure 2 ) appeared to represent independent predictors of poor prognosis (Table 4) . We therefore defined our intermediate risk population as that population of patients without either poor or good risk cytogenetics, not having an Flt3/ITD with an age of 60 years or younger. Analysis of the failure-free survival of Table 4 Relative hazards within the total study population as calculated by Cox regression analysis Figure 3 . Although the autonomous proliferation was a significant predictor for survival within the total primary AML population this parameter was not a significant predictor within the intermediate risk population. On the other hand two of the tested cytokines, ie M-CSF and Il-1␣ were shown to be significant predictors within this population (Table 5) . In univariate analysis, stratification of the patients in low and high responders at an optimal cut-point of 300 and 400 c.p.m. for Il-1␣ and M-CSF respectively, proved both growth factors to be good predictors for both failure-free and overall survival (Figures 4 and 5) . These figures also show the initial therapy response of high and low responders to both Il-1␣ and M-CSF not to be different. However, at a median observation time of 15 months, significantly different relapse rates could be observed (Table 6 ). Relapse rates varied from 5/21 and 4/17 (24%) for the low responder groups of M-CSF and Il-1␣ respectively to 5/5 (100%) for the M-CSF high responder population and 6/9 (67%) for the Il-1␣ high responder population.
Discussion
In the past few years much progression has been made in the identification of specific genetic defects, such as Flt3/ITD, AML-1-CBF␤ PML-RAR and various others, their respective role in the pathogenesis of AML and their clinical prognostic impact. Notwithstanding, there is a large population of patients who cannot be stratified in specific cytogenetic risk groups. According to the conventional cytogenetic risk stratification there is a large number of patients with no detectable aberrations or with aberrations without prognostic value. Such patients are currently considered to have an 'intermediate The response to therapy at the median observation time of 15 months was determined for each of the indicated response groups. No CR, patients who failed to respond to therapy or only had a partial response. CR, the number of patients who still showed a complete remission. Relapse, the number of patients who had relapsed before the median observation period.
Leukemia risk'. This group is probably heterogeneous and includes a mixture of favourable and unfavourable risk individuals. Hematopoietic growth factors may stimulate the in vitro proliferation of AML. 26, 27 Correlations between the in vitro cytokine responsiveness and patient prognosis have been previously been reported. [28] [29] [30] Our observation that patients with a Flt3/ITD comprise a 'low' cytokine responder population coupled to a poor prognosis, combined with the poor prognosis of patients with an age over 60 years, led us to define our intermediate risk population as that population of primary AML patients with an age below 60 years not having a tandem duplication in the Flt3 gene and with intermediate risk cytogenetics. Here, we show that among this intermediate risk population, poor and good risk patient prognosis can be further stratified based on the short-term (7-day) in vitro response to either G-CSF or IL-1␣. Our observation that the autonomous proliferation, although predictive in the total study population, was not predictive in the intermediate risk population could not be explained by the absence of a specific high autonomous responder, poor prognosis, population in our intermediate risk population (data not shown).
Although the survival curves of both M-CSF and Il-1␣ resemble each other (Figures 4 and 5) , analysis of the individual patients showed different responses to both growth factors, ie patients within the high responder population after Il-1 stimulation could be low responders after M-CSF stimulation and vice versa (data not shown).
As calculated from the Kaplan-Meier survival analysis within the subpopulation of the redefined intermediate risk patients, the low responder groups had a 4-year OS of around 60-80% whilst the 4-year FFS of these groups varied between 60 and 70% percent. This is in sharp contrast with the high responder populations where these values were between 0 and 10% for both OS and FFS. The difference in the FFS of the intermediate risk population was also visible when calculating the median duration of the FFS (Table 7) . In both cytokine combinations the median FFS for the low responder groups was over 60 months whilst this value was around 6-7 months for the high responders. In the cytokine responses that were found to be predictive, the better prognosis of the low responder group was not based on an increased initial therapy response. Rather, high responders had both a shorter FFS and an increased relapse rate. However, the biological significance in AML progression or AML relapse of both the autonomous and M-CSF or IL-1␣ induced response observed in vitro would require further study. As cytokine responses might be limited in time we also studied the cytokine responses after 3 days in vitro culture (data not shown). Although we did observe differences in the levels of responses (both increases and decreases were found when compared to day 7) neither of the cytokines tested at this timepoint was predictive for survival.
In the present study, we have focused on the total primary AML population and the population with an intermediate risk.
We argued that the subclassification of the latter population into variable prognosis subgroups would be clinically most relevant. We also showed, that a poor patient prognosis is not linked to high overall cytokine responses of the patients AMLblasts, as is indicated by the significance of both M-CSF and Il-1 which only caused a modest proliferation in most samples (see Table 2 ). To date, the median follow-up period of our patient population is 15 months, which limits the predictive value of our experiments. Therefore, we plan to extend the observation period in the near future.
In conclusion, our present data indicate that within the intermediate risk group additional risk stratification is possible. Despite the fact that further follow-up of especially the good risk groups is required to study their disease progression over a prolonged period of time, we consider the detection of a high responder 'poor risk' population in the intermediate risk group to be of importance. Whilst the initial therapy response of the patients within this population equals that of the other response groups, they are characterized by an increased relapse rate as well as a shorter overall and failure-free survival. If further study extends and supports our data, it should be considered to include these patients in the poor risk arms of treatment protocols and offer them intensified treatment or bone marrow transplantation.
